AMICUS THERAPEUTICS, INC. — Director's Dealing 2023

Jan 17, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2023-01-13

Reporting Person: MCGLYNN MARGARET G (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-13	Common Stock	M	15000	$3.32	Acquired	65705	Direct
2023-01-13	Common Stock	S	15000	$13.0258	Disposed	50705	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-13	Stock Options (right to buy)	$3.32	M	15000	Disposed	2023-06-13	Common Stock (15000)	Direct

Footnotes

F1: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.00 to $13.10 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: All of these options were fully vested and exercisable as of the transaction date.